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Abstract
Background: Cyclooxygenase (cox) is the rate-limiting enzyme, which catalyzes the conversion of arachidonic acid
into prostaglandins and contributes to the inflammatory process. Cyclooxygenase-2 (cox-2), which is one of the
two isoforms, plays a role in tumor progression and carcinogenesis. p53 contributes to apoptosis, DNA renewal
and cell cycle. Studies concerning the relationship of cox-2 and p53 expressions and carcinogenesis are available,
but the association between cox-2 and p53 in Hodgkin lymphoma (HL) is not exactly known.
In our study, we examined the association of cox-2 and p53 expression, with age, stage, histopathological subtype,
and survival in HL. We also examined correlation between cox-2 and p53 expression.
Methods: Cox-2 and p53 expressions in Hodgkin-Reed Sternberg cells (HRS) were examined in 54 patients with HL
depending on cox-2 expression, stained cases were classified as positive, and unstained cases as negative. Nuclear
staining of HRS cells with p53 was evaluated as positive. The classifications of positivity were as follows: negative
if<10%; (1+) if 10-25%; (2+) if 25-50%; (3+) if 50-75%, (4+) if >75%.
Results: Cox-2 and p53 expressions were found in 49 (80%) and 29 (46%) patients, respectively. There were
differences between histological subtypes according to cox-2 expression (p = 0.012). Mixed cellular (MC) and
nodular sclerosing (NS) subtypes were seen most of the patients and cox-2 expression was evaluated mostly in the
mixed cellular subtype.
There were no statistically significant relationships between p53 and the histopathological subtypes; or between
p53, cox-2 and the factors including stage, age and survival; or between p53 and cox-2 expression (p > 0.05).
Conclusion: Considering the significant relationship between the cox-2 expression and the subtypes of HL, cox-2
expression is higher in MC and NS subtypes. However the difference between these two subtypes was not
significant. This submission must be advocated by studies with large series
Introduction
Hodgkin lymphomas (HL) are malignancies derived
from neoplastic Reed Sternberg (RS) cells which are
found in the inflammatory media consist of plasma
cells, eosinophils and histiocytes. The RS and its var-
iant Hodgkin (H) cells form 1-3% of the whole mass
[1]. It generates about 1% of the overall cancers and
30% of the lymphoid malignancies [1,2]. In the poly-
merase chain reaction (PCR) analyses performed to
determine the function and histogenesis of Hodgkin-
Reed Sternberg (HRS) cells, it is estimated that these
cells are originated from the germinal center B cells
a n dt h e yh a v es o m a t i c a l l ymutated immunoglobulin
(Ig) gene rearrangements. Not only the Ig expression
levels of the HRS cells which are identified as B cells,
but also their levels of transcription that is mediated
by inactivation of Ig promoters, are disturbed. It is
reported that HRS cells can block the apoptosis
through an apoptotic mechanism which is not clearly
understood, when the normal B cells go into apoptosis
after loosing their capacity of Ig expression. It is
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(EBV) infection and the nuclear factor kappa B (NFkB)
released from HRS cells also act through this way
[1,3-6].
Although various factors for the etiology have been
widely studied, it is estimated that EBV infection contri-
butes in some of the cases [2,3]. It is reported in large
series of epidemiologic studies that the risk of HL is
lower in people using anti-inflammatory drugs, com-
pared to the ones who do not use or who irregularly use
nonsteroidal anti-inflammatory drugs (NSAIDs) [3].
The best known target of NSAIDs is the cyclooxygen-
ase (cox) enzyme. Cox enzyme catalyzes the synthesis of
prostaglandins (PGs) from arachidonic acid. Two iso-
forms of the cox gene have been identified. Cyclooxygen-
ase-1(cox-1) is constitutively expressed on cell
membranes in normal tissues and related to physiological
functions, such as cytoprotection of the stomach and
control of platelet aggregation: and cyclooxygenase-2
(cox-2) is cytoplasmic in location, not detectable in most
of the normal tissues and induced by inflammatory and
mitogenic stimuli. Furthermore expression of cox-2 is sti-
mulated by oncogenes, growth factors, cytokines, tumor
promoters and it has been shown to inhibit apoptosis
[7,8]. In several tumors such as colon, esophagus, sto-
m a c h ,c e r v i xa n db r e a s t ,c o x - 2i sf o u n dt ob ea s s o c i a t e d
with carcinogenesis and tumor progression [7,9-14].
The p53 gene located on the short arm of chromo-
some 17 has been described as a tumor suppressor gene
producing a 53 kD nuclear binding protein [15,16]. It is
thought that p53 has a role in regulation of normal cell
cycle, apoptosis and in response to DNA damage [16]. It
leads to selective growth and tumor formation by the
replication of mutant p53 and deregulating cell cycle
[17]. It is reported that mutant p53 acts by changing the
genetic structure in lung, breast, pancreas and lymphoid
malignancies [5,16,17]. It is declared in the previous stu-
dies that there might be p53 mutations and the antia-
poptotic effect of p53, in the HRS cells [5,18,19].
The aim of our study is to determine the association
between cox-2 and p53 expressions with the histological
subtypes, age, survival and tumor dissemination, in HL
cases.
Materials and methods
In this study, a total of 54 patients were enrolled who
were diagnosed with HL in Dr. Lutfi Kirdar Kartal Edu-
cation and Research Hospital and University of Mar-
mara Medical School between 2000 and 2007.
The cases were classified according to age, survival,
stage and the histological subtypes.
Ann Arbor staging system was performed for classifi-
cation, and staging results were obtained from the
patients’ files. All samples were fixed in formalin and
embedded in paraffin. The histological slides of all of
the patients were reviewed by two blinded pathologists
and categorized according to the WHO classification of
hematological malignancies into nodular lymphocyte
predominant (NLP), nodular sclerosing (NS), lympho-
cyte-rich (LR), mixed cellular (MC) and lymphocyte
depleted (LD) type [1]. After preparing the slides form
the appropriate paraffin block, immunohistochemical
assessment was performed for cox-2 and p53, for diag-
nostic evaluation.
Immunohistochemistry
Three μ thick sections were placed on 3-aminopropylethy-
lene-covered slides and deparaffinized at 60°C for 1 hour.
The slides were dipped in xylol for 15 minutes for deparaf-
finization, soaked with alcohols for 15 minutes and washed
in distilled water. Afterwards, they were applied in pH 6
citrate buffer for antigen retrieval process in microwave
oven for 20 minutes. Endogenous peroxidase activity was
blocked by 10 minutes of incubation with 3% hidrogen
peroxidase. To prevent nonspecific bindings, blockage was
performed for 10 minutes (Dako Cytomation protein
block serum-free, ref × 0909, lot 10016138, Denmark).
Cox-2 was incubated with monoclonal mouse anti-human
(Dako Cytomation EnVision Clone CX294, Code M3617,
1:100 dilution for 90 min, Denmark). They were incubated
for 30 minutes with polyvalent HRP polymer (Spring
Bioscience cat: DPE-125, Lot: 70918, California). P53 was
incubated with monoclonal mouse anti-human (Dako
Cytomatin En Vision Clone DO-7, Code N1581 ready-to-
use for 30 min, Denmark)
AEC chromogen system was applied to slides for 15
minutes (Spring Bioscience catalog: ASS-125 ready to
use, California). Contrast staining was done with mayer-
hematoxylene and slides were covered with water-based
cover material.
Evaluation of immunostaining
The cases, in which cytoplasmic cox-2 expressions were
determined in their HRS cells, were accepted as positive.
RS cells are large with variable amount of cytoplasm
that is eosinophilic or amphophilic. The nuclei are large
thick nuclear membranes. Also there can be two nuclei,
symmetric with ‘’mirror image” appearance. On the
other hand H cells mono nuclei or multinuclei and
these cells have positive staining with CD15 or and
CD30 antibodies in immunohistochemical staining.
Nuclear staining of p53 was evaluated as follows: nega-
tive if <10%; (1+) if 10-25%; (2+) if 25-50%; (3+) if 50-
75%; (4+) if >75% of HRS cells were positive [7].
Statistical analysis
Statistical analyzes were performed using SPSS 13.0.
Chi-square test was used in the comparison of classified
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methods (median range). Survival analyses were per-
formed using the Kaplan-Meier method. Results were
evaluated in 95% confidence interval and p < 0.05 was
determined as the level of significance.
Results
Patients and follow-up
This study included 54 patients: the mean age at diagno-
sis was 37 years. In accordance with the histological
subtypes, there were 26 (48.1%) cases of NS subtype, 24
(44.4%) cases of MC subtype, 3 (5.6%) cases of LR sub-
type, and 1 (1.9%) case of NLPHL. Data from clinical
follow-up were obtained in 23 patients, up to 66
months. The mean follow-up was 39 (5-66) months.
Among 23 patients, there were 20 (90%) cases admi-
nistered with ABVD, 1 (4.5%) case with ABVD+CMOPP
and 1 (4.5%) case with ABVD+CBVP-K. Three (13%)
cases were in stage I, 6 (26.1%) cases were in stage II,
10 (43.5%) cases were in stage III and 4 (17.4%) cases
were in stage IV. 9 (39%) cases were administered with
RT but 14 (60.9%) cases were not (table 1).
Cox-2 and p53 expression
Immunoreactivity with Cox-2 was seen in 49 (80%) of
the 54 cases with HL (figure 1). On the other hand p53
staining was seen in 26 (48%) of the 54 cases (figure 2).
Significant relationship was determined between the
cox-2 expression and the histological subtypes (p =
0.012). Considering the NS and MC subtypes, which
generate the majority of the cases, MC subtype demon-
strated more staining than NS subtype. However there
is no statistically significant difference between NS and
MC subtypes considering cox-2 expression (p = 0.61).
All cases were stained with cox-2 in lymphocyte rich
type which generates the minority of the cases. However
no staining was detected in NLP type. No statistically
significant results were derived from the evaluation of
cox-2 expression according to their stages in 23 cases
who had complete follow-up (p = 0.142). Evaluating the
cox-2 expression in terms of age, 24 cases were <35 and
30 patients were >35 years old. There was no statisti-
cally significant relationship between the cox-2 expres-
sion and age (p = 0.367). The association of cox-2
expression with the histological subtypes, stage and age
are presented on table 2. No significant relationship was
detected between p53 and the histological subtypes,
stage and age (p > 0.05) (table 3).
The association between cox-2 and p53 expression
The association between cox-2 expression and p53 is
evaluated, but no statistically significant relationship was
detected (p > 0.05) (table 4).
The association between cox-2 expression and survival
Five years survival was 87.7%, in the follow-up group.
The median overall survival could not be achieved (fig-
ure 3).
The effects of p53 and cox-2 expressions on survival
have been investigated as well, but statistically signifi-
cant results were not obtained, due to the small number
of the potentially follow-up group and death of only two
of the patients.
Discussion
It is known that cox-2 acts in tumor mechanisms
including tumor proliferation, differentiation, immuno-
supression, angiogenesis and inhibition of apoptosis, by
synthesis of PGs [20]. In the previous studies it has been
demonstrated that cox-2 expression increases in colon,
stomach, esophagus, lung, over, cervix, liver, pancreas
adenocarcinomas and brain tumors and it is reported as
an e g a t i v ep r o g n o s t i cp a r ameter [12,13,21-24]. More-
over, it is reported in epidemiologic and experimental
studies that cox-2 inhibitors and NSAIDs prevent the
carcinogenesis [9-11,13,14,20,21,25,26]. A great number
of studies regarding the solid organ tumors are available,
however, there are very little numbers of studies pre-
sented concerning the hematological malignancies in
association with the cox-2 expression, and thus the rela-
tionship between the lymphoid malignancies and the
cox-2 expression is not clearly understood.
Ohsava et al., Hsu et al., and Hazar et al. observed the
cox-2 expressions in classical Hodgkin lymphoma (CHL)
and detected cytoplasmic cox-2 expression in 7(70%) of
10 CHL cases, 7(70%) of 10 CHL cases 15 (48%) of 31
Table 1 Distrubution of Parameters
N%
Age (n = 54) ≤ 35 years 24 44,4
>35 years 30 55,6
Histological type (n = 54) NS 26 48,1
MC 24 44,4
LR 3 5,6
NLP 1 1,9
Therapy (n = 22) ABVD 20 91,0
ABVD+CMOPP 1 4,5
ABVD+ CBVP-K 1 4,5
Stage (n = 23) 1 3 13,0
2 6 26,1
3 10 43,5
4 4 17,4
Bulky (n = 23) Yes 2 8,7
No 21 91,3
RT (n = 23) Yes 9 39,1
No 14 60,9
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Figure 2 (p53 × 100) p53 expression in H/R-S cells.
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expression was determined in 49 (80%) patients among
the 54 HL cases.
It is emphasized that cox-2 increases the expression of
angiogenic factors such as PGE2, as well as the expres-
sion of proangiogenic factors; and also that PGE2 is a
strong vascular endothelial growth factor (VEGF) indu-
cer and consequently cox-2 contributes to angiogenesis
and increases the tumor proliferation [7,13,22].
The study of Ohsawa et al. on this point investigated
the cox-2 expression in association with proliferation
index and microvessel density, and demonstrated that
Ki67 proliferation index and the microvessel density
w e r e2a n d4f o l d sg r e a t e ri nc o x - 2e x p r e s s i n gg r o u p
[7]. It is known that interleukin-1 (IL-1), interleukin-5
(IL-5), NFkB, granulocyte colony stimulating factor,
tumor necrosis factor and many other cytokines are
released from the HRS cells (1,28). These cytokines
result in B symptoms such as fever, sweating and weight
loss which are included within the negative prognostic
parameters [1]. Hazar et al. evaluated the association of
cox-2 with histological type, age, stage and the response
to the therapy. They obtained a lesser response to the
therapy in non-HL cases with cox-2 expression and
reported cox-2 expression as a negative prognostic para-
meter [27]. In our study, the association of cox-2 with
histological subtypes was investigated and a greater
staining was determined in the MC subtype which gen-
erates the majority among the overall groups. Since the
cytokines are known to induce the cox-2 expression, we
can accept that MC type (except lymphocyte poor type)
involves more HRS cells, and therefore releases more
cytokines compared to the other types. However there is
no statistically significant difference between NS and
MC subtypes considering cox-2 expression (p = 0.61).
With regard to the fact that negative prognostic features
such as advanced stage and contiguity dissemination are
more often observed in the MC type. In our study, the
association of age and survival with cox-2 expression
was observed, but no statistically significant relation-
ships were obtained however higher level of cox-2
expression in MC type was noteworthy.
It is suggested that p53 plays an important role in
cell-cycle control, maintenance of genomic stability, cell
differentiation and programmed cell-death. The muta-
tion or depletion of p53 oncogen is one of the most fre-
quently reported lesions in various types of cancers
[4,7,15,16,28,29].
Generally it is accepted that, most of the mutations of
the p53 gene result in production of a mutant p53 pro-
tein. The half time of the mutant p53 protein is
extended; therefore the cells tend to accumulate.
Reports about the abnormal accumulation of p53 in
HRS cells are available [2,4,19]. Moreover, the p53 gene
mutations may lead to the disturbance of p53 mediated
transactivation and this evidence may considered to be
the key factor of apoptosis resistance of the p53 gene
mutation. However, the association between the high
levels of the p53 protein and p53 mutations could not
be determined in some of the studies [4]. In a study car-
ried out by Rongen et al., the p53 gene was evaluated in
8 CHL cases and 6 (80%) of them demonstrated p53
gene mutations in their HRS cells [5].
Table 2 The association of Cox-2 expression with the
histological subtypes, stage and age
COX-2 expression
(negative) n%
COX-2 expression
(positive) n%
p
value
Histologic
type
0.012*
LR 0(100) 3(100)
MC 1(4.2) 23(95.8)
NS 3(11.6) 23(88.4)
NLP 1(100) 0(0)
Stage 0.142
Stage I-II 2(22.2) 7(77.8)
StageIII-IV 0(0) 14(100)
Age 0.367
<35 1 23
>35 4 26
* Chi-square test p < 0.05
Table 3 Histological type, stage, age and p 53 expression
P53 expression
(negative) n%
P53 expression
(positive)n %
p
value
Histologic
type
0.078
LR 3(100) 0(0)
MC 15(62.5) 9(37.5)
NS 10(38.5) 16(61.5)
NLP 0(0) 1(100)
Stage 0.669
StageI-II 3(33.3) 6(66.7)
StageIII-IV 7(50) 7(50)
Age 0.548
<35 11(45.7) 13(44.3)
>35 17(56.6) 13(53.4)
+ Chi-square test p < 0.05
Table 4 The association between cox-2 and p53
expression
P5 3
expression
COX-2 expression
(negative) n%
COX-2 expression
(positive) n%
P
value
Negative 2(7.1) 26(92.9) 0.663
Positive 3(11.5) 23(88.5)
Total 5 49
+ Chi-square test p > 0.05
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shown in 36 (72%) cases among the 50 CHL patients
in the study of Gupta et al., in all of the 67 CHL
patients in the study of Magio et al. and in 14 (42%)
cases among the 33 CHL patients in the study of
Ohsawa et al. [7,16,19]. Wang et al. evaluated the asso-
ciation of p53 with the clinical stage, EBV, bcl-2, reti-
noblastoma gene, p21, Ki67 and topoisomerase-II-alfa
and detected p53 gene in 14 patients among the 62
CHL cases. They have detected p53 expression more
frequently in stage I, but in a lesser frequency in the
advanced stages such as stage III and IV. However, no
significant relationship was found between the clinical
stages, histological subtypes and the p53 [4]. In this
s t u d yi ti sr e p o r t e dt h a tt h er a t eo fp 5 3e x p r e s s i o ni s
small; therefore abnormal p53 protein expression may
not be effective in the blockage of apoptosis mediated
deaths of HRS cells [4]. In our study, p53 expression
was detected in 26 (48%) of the 54 cases, but no asso-
ciation was determined with the histological subtype,
the stage, age and survival.
Association of cox-2 and p53 was reported in the stu-
dies previously performed. Subbaramaiah et al., com-
pared the cox-2 expression between the wild type (wt)
p53, mutant p53 and p53 non-expressing mouse fibro-
blasts and discovered that cox-2 expression was mark-
e d l yr e p r e s s e db yw tp 5 3 .T h e yt h o u g h tt h a tt h i s
investigation may describe why these levels of cox-2
protein are not seen in normal epithelial cells and con-
trarily why mutant p53 increases the levels of cox-2
expression in malignant tissues. They reported that the
cytokines in mutant p53 expressing cells, oncogenes and
growth factors can increase cox-2 induction [18].
There are also studies available investigating the cox-2
and p53 expressions in ovarian adenocarcinoma and in
head and neck tumors and a positive association
between cox-2 and p53 was reported [17,20].
However, Ohsawa et al. did not determine an associa-
tion between cox-2 and p53 expression [7]. In our
study, the association between p53 and cox-2 is also
investigated, but no statistically significant evidence was
found (p = 0.663).
Consequently, evaluating the association between the
histological subtypes and cox-2 expression, statistically
significant association between histological subtypes
and cox-2 was determined. However, considering both
cox-2 and p53, significant association of cox-2 and p53
with age, stage and survival were not detected. Median
follow-up was 36 months, in our study and it was
below 5 years of follow-up. The statistically significant
association between cox-2 and histological types is
promising, nevertheless, for the corroboration of the
data and in support of including the cox-2 in prognos-
tic parameters, long term follow-up studies with large
series are needed. We think that our study is elucidat-
ing in this aspect.
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